Abstract
Motivation Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease, 2019; COVID-19) is associated with adverse outcomes in patients. It has been observed that lethality seems to be related to the age of patients. Moreover, it has been demonstrated that ageing causes some modifications at a molecular level.
Objective The study aims to shed out light on a possible link between the increased COVID-19 lethality and the molecular changes that occur in elderly people.
Methods We considered public datasets on ageing-related genes and their expression at tissue level. We selected interactors that are known to be related to ageing process. Then, we performed a network-based analysis to identify interactors significantly related to both SARS-CoV-2 and ageing. Finally, we investigated changes on the expression level of coding genes at tissue, gender and age level.
Results We observed a significant intersection between some SARS-CoV-2 interactors and ageing-related genes suggesting that those genes are particularly affected by COVID-19 infection. Our analysis evidenced that virus infection particularly affects ageing molecular mechanisms centred around proteins EEF2, NPM1, HMGA1, HMGA2, APEX1, CHEK1, PRKDC, and GPX4. We found that HMGA1, and NPM1 have a different expression in lung of males, while HMGA1, APEX1, CHEK1, EEF2, and NPM1 present changes in expression in males due to aging effects.
Conclusion Our study generated a mechanistic framework to explaining the correlation between COVID-19 incidence in elderly patients and molecular mechanisms of ageing. This will provide testable hypotheses for future investigation and pharmacological solutions tailored on specific age ranges.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We do not received external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used only insilico data sto there is not the need to IRB or approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used have been downloaded from public databases we cited in the manuscript.
